Dasatinib in chronic myelogenous leukemia.
Kathula
Satheesh K
SK
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000069439:Dasatinib; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D019152:Paracentesis; D010996:Pleural Effusion / Q000139:chemically induced*; D018700:Pleurodesis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib